The capsule application, entitled “Dual Compartment Capsule for the Administration of Orlistat”, was granted the petition “to make special” by the office, and an examination can be expected within one year, whereas routine examinations currently require more than three years.
The Vancouver-based drug firm successfully completed the design and engineering of the capsule for its C-103 weight loss drug back in April.
The dual compartment gelatin capsule allows for the release of three separate ingredients – orlistat, simethicone and activated charcoal – in a unique sequence.
Side effects from orlistat, including bowel irritation, are well-documented and M hopes this new delivery system will help to reduce these adverse effects.
“Our experienced team of doctors and scientists has been working diligently to develop a precise dual compartment capsule for the delivery of our C-103 technology, re-formulated orlistat,” said Gary Thompson, president & chief executive officer of M Pharmaceutical USA Inc.
“The resulting design of our dual compartment capsule has been described by industry experts as ‘unique’, and ‘innovative’. We are now excited to have patent-pending status for this design in over 150 countries around the world,” Thompson said.
“This new design means we can engage immediately with prospective capsule manufacturing partners, allowing us to advance to clinical trials and commercialization,” he added.
Shares in the company were up 5.9% at C$0.09.
Story by ProactiveInvestors